Aktis Oncology, Inc. (AKTS) Stock Score, Valuation & Financial Research
Aktis Oncology, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for AKTS
Aktis Oncology, Inc. currently has a Wall Street Score of 33/100. The stored market price is $22.71. Its financial score is 26/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Aktis Oncology, Inc. does
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumor
AKTS financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $22.71
- Market capitalization:
- $1.21B
- Revenue:
- $10.1M
- Net income:
- $-73.1M
- Free cash flow:
- $-73.7M
- Cash:
- $82.5M
- Total debt:
- $11.2M
- EPS:
- -1.05
- Financial score:
- 26/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +0.5%.
- Free cash flow is $-73.7M, showing cash burn in the current stored period.
- The balance sheet shows $82.5M of cash versus $11.2M of total debt, leaving more cash than debt.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 26/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AKTS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.